Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

SCYNEXIS (0L49) Share Price & Analysis

0L49 Stock Chart & Stats

$3.85-$0.01(-0.26%)
At close: 4:30 PM GMT
$4$5$63 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$3.68 - $3.85
52-Week Range
$3.59 - $9.20
Previous Close
$3.86
Volume
11.29K
Average Volume (3M)
8,145
Market Cap
$37.51M
Enterprise Value
-$4.09M
Total Cash (Recent Filing)
$54.08M
Total Debt (Recent Filing)
$1.95M
Price to Earnings (P/E)
―
Beta
0.87
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.72
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Non-dilutive Pipeline Funding

The BARDA cost-share contract can fund eligible development and administrative expenses while advancing SCY-247 and SCY-770 into Phase 2. If options are exercised, this support could reduce financing pressure, extend development capacity, and strengthen the antifungal pipeline without relying solely on equity issuance.

Conservative Leverage

Very low debt relative to equity gives SCYNEXIS greater financial flexibility while it develops and commercializes antifungal assets. Limited leverage reduces mandatory financing burdens and leaves more capacity to direct capital toward clinical programs, although continued losses could still erode the equity base over time.

Experienced Biopharma Governance

Adding a director with extensive drug-development and biotechnology leadership experience can improve strategic oversight as SCYNEXIS advances rare-disease and antifungal programs. His background is particularly relevant to clinical execution, regulatory planning, and portfolio decisions that may shape longer-term commercialization outcomes.

Bears Say

Persistent Unprofitability

The current earnings profile is not self-sustaining: substantial net, EBIT, and EBITDA losses indicate that operating expenses remain far above generated revenue. Unless commercialization or licensing economics improve materially, ongoing losses could consume equity and limit the company’s ability to fund its pipeline independently.

Negative Cash Generation

SCYNEXIS is currently consuming cash rather than funding operations internally, leaving clinical development dependent on financing, partnerships, or external support. Although free cash flow improved versus 2024, the reversal from strong 2023 cash generation highlights volatility and continuing execution and funding risk.

Unstable Revenue And Earnings

The sharp revenue deterioration and repeated return to losses after 2023 suggest that prior performance has not yet translated into a durable earnings base. Such volatility makes planning and reinvestment more difficult and increases dependence on successful product adoption, licensing activity, or development funding.

SCYNEXIS News

0L49 FAQ

What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $3.59 and its highest was $9.20 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $37.51M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 10 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -9.528%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in GB:0L49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology